Monday, September 29, 2008

New MS Drug Shows Promise

MS Drug Clears Hurdle

Laquinimod Treatment Could One Day Offer Alternative to Injections

June 20, 2008 -- A new drug called laquinimod appears to be a promising treatment option for adults with the most common form of multiple sclerosis (MS).

Phase II study results published in this week's edition of The Lancet show that laquinimod tablets safely and effectively reduce disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Current MS treatments must be given by injection.

MS is an autoimmune disease that damages the central nervous system. The body's immune (defense) system attacks myelin, the material that covers and protects nerve fibers. Nerve damage and inflammation gets worse over time, and leads to symptoms such as numbness, tingling, fatigue, loss of vision, and in severe cases, paralysis. People with the relapsing-remitting form of the disease have flare-ups followed by times of partial or complete recovery. According to the National MS Society, about 85% of people are first diagnosed with this form of MS.

The international study involved 306 adults aged 18 to 50. Patients could participate if they had one or more flare-ups in the previous year and at least one MS lesion visible on a special MRI test called a gadolinium-enhancing (GdE) scan. The study did not look at clinical disability.
Researchers randomly assigned patients to one of two doses of laquinimod (0.3 or 0.6 milligrams) or a placebo (fake pill).

The patients received brain MRI scans and clinical assessments before and several times during the study so researchers could monitor brain lesions, which would help them determine the drug's effectiveness. Scans were done every four weeks for nine months.

Giancarlo Comi of the Institute of Experimental Neurology at the University Vita-Salute in Milan, Italy, and colleagues found that, compared with placebo, patients who received the higher dose of laquinimod had more than a 40% reduction in the average number of GdE lesions over the last four scans compared with the one taken at the study's start. There were no statistically significant effects seen between patients who took the lower dose of laquinimod and the fake pill.
Treatment appeared well tolerated. Researchers reported no deaths. One patient had a pre-existing blood clotting disorder and developed a clot of a large vein that carries blood from the liver. The drug was stopped and the patient was treated with blood-thinning medication. Two patients had high levels of liver enzymes.

"Overall, the efficacy and safety profile emerging from this and from a previous phase II clinical trial, in combination with the oral route of administration, make laquinimod a promising therapeutic opportunity for patients with relapse remitting multiple sclerosis," the researchers concluded in the journal article.

A larger-scale phase III trial to examine the benefits and risks of laquinimod treatment is under way.

In an accompanying comment, Mayo Clinic researchers B. Mark Keegan and Brian G. Weinshenker said that further studies are needed to compare laquinimod "head-to-head" to existing MS treatments to see if the new drug is superior or just as effective.

Source: WebMd.com
http://www.webmd.com/multiple-sclerosis/news/20080620/ms-drug-clears-hurdle?ecd=wnl_mls_092608

I am excited, who wouldn't want to take a pill instead of an injection?! *jumping up and down with my hand raised saying, "me, me, me"*

Friday, September 19, 2008

September?!

I know, it has been a very long time since I posted anything, but in regard to multiple sclerosis, things have been pretty boring. Everything has remained relatively consistent (no relapses) so that is great.

As for my last neurology appointment back on 4/10/08 in NY, things checked out find there; however, the doctor was unable to recommend a neurologist. I was given a telephone number to call and that was it.. oh well. I still have to call and get a new one since we've moved.

There hasn't been anything to post on regarding my medical condition; however, there are some miscellaneous things I can tell you about...

Casey graduated from medical school 5/19/08 and then we began packing up and getting ready to move. *Can you believe it, he's a doctor!?* A few days after his graduation, we moved to Berkley, MI. After being in MI for just a few days, we flew off to CA for, well, pretty much all of June. We had a ton of things to do while we were in CA, one of those many things included looking for a place to have our wedding and reception. YUP.. we're getting married! We got engaged 4/17/08. The wedding date is September 26, 2009 in Walnut Creek, CA. Oh wedding planning, why does it have to be so stressful?

Anyway, life is progressing, and fortunately my multiple sclerosis isn't, well not in a negative way and that is wonderful. :)

Wednesday, December 19, 2007

12/19/07

Yesterday was my six-month neurology check-up with Dr. Aziz. It was pretty uneventful, but uneventful is good! He said everything sounds fine and that is always great to hear. I asked him when my next MRI would be, and he said he doesn't go by a schedule but by how I am feeling and whether or not if things are changing -- if I want to get an MRI he would schedule for one to be done, or if he thinks one needed to be done. So that is nice, no unnecessary tests to be performed nor being subject to a generic timeline of what needs to be done and when.

I scheduled my next appointment for 4/10/08. I did ask Dr. Aziz if he wouldn't mind giving a recommendation for a neurologist once we knew where we will be moving. So, once Casey's Match Day (3/20/08) has come and gone and we know where we will be off to next, I will give Dr. Aziz a call so he can look into recommendations. It will be sad to change doctors because I have been happy with Dr. Aziz, but I am sure he will give a good recommendation. If not, I can always find a different neurologist.

Casey & I are now going to start packing for our trip back to the west coast for Christmas. Our flight is scheduled to leave Syracuse at 6:25 a.m. on Friday, 12/21/07 and we arrive in Seattle at about 11 a.m. Friday will be a long day for us! Fortunatly, we don't have to leave until the morning of Friday, 1/4/08. It will be a nice long break away from Syracuse along with the snow & cold. It is always hard to leave WA, but it is always nice to come back to our pets and our space.

We're almost done with this piece of the adventure and will soon be off to the next part of the adventure (and one of us will have transformed into a Doctor!)....

Thursday, October 18, 2007

Not much going on

It has been a while since I posted anything, which is a good thing - right?. There hasn't been anything to post on regarding my medical condition; however, there are some miscellaneous things I can tell you about...

Next Thursday, 10/26/07, Casey and I are going to another MS seminar on "Optic Neuritis & MS". If I remember correctly, my neurologist said I had optic neuritis in my right eye. I say 'another' seminar because on 9/25/07 we went to our first MS seminar which was on "Balance Issues". I do not I have any balance issues, but we thought it would be good to get involved with a local MS group. It was interesting. We couldn't help to notice I was the youngest person attending the seminar with MS. Regardless, it was the first time I was able to see others who had some form of MS (I don't know who had what form), both women and men. Of course, there were more women and men in attendance, which is to be expected since the disease is more common in women.

Anyway, I hope the 10/25 seminar is more interesting than the last one. Dr. Luis Mejico, a neuro-opthalmologists from SUNY Upstate Medical Center (yup, where Casey is going to Med School), is the presenter. Casey said he is gave a lecture a few days ago at Upstate and he found him to be an entertaining speaker as well as a pretty down-to-earth nice guy.

What is optic neuritis?


Optic neuritis is the inflammation of the optic nerve, the nerve located in the back of the eye that transmits light and visual images to the brain and is responsible for vision. According to the National Multiple Sclerosis Society, 55% of people with MS will have an episode of optic neuritis. Frequently, it's the first symptom of the disease. Although having optic neuritis is very suggestive of MS, it does not mean that a person has or will get MS.

The symptoms of optic neuritis are the acute onset of any of the following:

  • Pain in the eye
  • Blurred vision
  • Graying of vision
  • Blindness in one eye

It's rare that both eyes are affected simultaneously. Loss of vision tends to worsen over the course of a few days before getting better. This usually takes about 4-12 weeks. Treatment may include intravenous and/or oral steroids to control the inflammation.

Source: WebMd.com


FYI: For additional reading on optic neuritis, click the following link to WebMD's website for a short 'blip' on "Multiple Sclerosis and Vision Problems": http://www.webmd.com/multiple-sclerosis/guide/multiple-sclerosis-vision-problems

Thursday, September 6, 2007

UGI results

Well yesterday I finally got the radiology consultation report. The transcriptionist seemed to be in a good mood since a few notations were funny:

Scout radiograph: Unremarkable.
Double-contrast upper GI: The esophagus, stomach and duodenum appeared normal. There is no evidence for mucosal thickening, ulcer or mass. Hiatal hernia and reflux were not seen.

Impression: (1.) Negative double-contras upper GI. (2.) No ulcer is seen in the stomach or duodenum.

Thank you for this referral.


So, I wonder what was going on.. at least there is not a 'mucosal thickening, ulcer or mass, hernia or reflux'.

Tuesday, September 4, 2007

Did I read this correctly?

I don't ususally post on emails I recieve, but I thought this WebMD email deserved a blog posting...


DNA Vaccine May Stop MS
In Early Test, Multiple Sclerosis Vaccine Turns off Harmful Immune Response

By Daniel J. DeNoon
Reviewed by Louise Chang, MD
WebMD Medical News

Aug. 13, 2007 – A new kind of vaccine promises to halt the destructive immune responses behind multiple sclerosis, type 1 diabetes, and other autoimmune diseases.

Thirty patients already have received four injections of the MS version of the vaccine in a phase 1 clinical trial. The vaccine was very safe, at least in the short term. And there was tantalizing evidence that it just might work.

Hideki Garren, MD, PhD, is one of four Stanford University researchers who invented the vaccine and co-founded Bayhill Therapeutics to develop it. Garren notes that MS is an autoimmune disease in which a specific kind of immune cells -- T cells -- attack nerve cells.

"Our vaccine is designed to go only after the disease-causing cells in MS and leave the other T cells alone," Garren, now Bayhill's vice president of research, tells WebMD. "The first advantage of this approach is we should have fewer side effects than current MS drugs. And second, this should modify the underlying disease because we are going after the disease-causing cells."

In MS patients, T cells attack the myelin sheath that protects nerve fibers. One of the T cells targets is a specific myelin protein -- an antigen -- called myelin basic protein or MBP.

The new vaccine is made of genetically engineered DNA that encodes MBP. Normal vaccines provoke immune responses against the antigens in the vaccine. But the Bayhill vaccine attaches the MBP DNA to a "backbone" cleverly designed to turn off immune responses instead of turning them on.

Sure enough, the vaccine did not make any of the patients' MS worse. In fact, MRI scans suggested that the treated patients had fewer MS brain lesions than those who got inactive placebo shots.

"We did see a trend in reduction of lesions," Garren says. "But these are just trends. Certainly this needs to be tested in larger trials."

Garren's team has just completed a phase II trial in which 290 patients received 13 doses of the vaccine over one year. They plan to report the results in October at a large European MS conference.

Emory University immunologist Brian D. Evavold, PhD, says the new vaccine definitely has an effect on the immune system. Evavold, an MS researcher, was not involved in the Garren study.

"To have antigen-specific targeting that turns off anti-myelin T cells is the Holy Grail of MS research," Evavold tells WebMD. "With a DNA vaccine you can do very targeted changes to the immune system. This would be a huge advance over what we can do right now."

"What WebMD readers can take from all this is that the future is very promising for new MS therapies," Garren says. "Many new drugs are in the pipeline and will soon be available. I would ask MS patients to keep an eye out for our vaccine because of the advantages it has."

If the new approach succeeds, it has implications far beyond MS. Evavold notes that many other autoimmune diseases -- such as type 1 diabetes, myasthenia gravis, and rheumatoid arthritis -- are caused by misguided immune cells.

The trick, Evavold says, is finding the specific antigen to which the T cells respond. Such antigens already are known for type 1 diabetes and myasthenia gravis. Indeed, Garren says his team has already begun a phase I trial of a DNA vaccine for type 1 diabetes. Those results won't be in for a year at least.

Garren and colleagues report the findings in the advance online edition of Archives of Neurology.



Source:
  • http://www.webmd.com/multiple-sclerosis/news/20070813/dna-vaccine-may-stop-ms?ecd=wnl_mls_090307